Fast Five Quiz: Early Non–Small Cell Lung Cancer

Daniel S. Schwartz, MD


May 24, 2022

Current NCCN guidelines advise that all patients with adenocarcinoma NSCLC have DNA mutational analysis EGFR mutations. EGFR is a growth factor receptor that induces cell differentiation and proliferation upon activation. Therefore, mutations of this receptor are significant because the use of EGFR tyrosine kinase inhibitors, such as osimertinib, is a viable first-line adjuvant treatment.

Thus, in addition to immunohistochemical analyses to identify tumor type and lineage, it is essential to conserve tissue for molecular testing.

Learn more about workup of NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.